<?xml version="1.0" encoding="UTF-8"?>
<!--REG30PARAB V1.0 (01-06-2026)-->
<xbrli:xbrl xmlns:in-capmkt="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt" xmlns:in-capmkt-ent="http://www.sebi.gov.in/xbrl/Regulation_30_Para_B_Of_Part_A_Of_Schedule_III/2026-04-30/in-capmkt/in-capmkt-ent" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-types="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.w3.org/1999/xlink"><link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2026-04-30.xsd"/><xbrli:context id="MainI"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">543220</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I_StageOfTheLitigationIsConcludedOrDisputeIsResolved"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">543220</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-07</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIIIAxis">in-capmkt:StageOfTheLitigationIsConcludedOrDisputeIsResolvedMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="I_DevelopmentInRelationToProceedings"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">543220</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-08-07</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="in-capmkt:StageOfTheLitigationIsConcludedOrDisputeIsResolvedAsPerSubPara8OfParaBAxis">in-capmkt:DevelopmentInRelationToProceedingsMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><in-capmkt:NSESymbol contextRef="MainI">MAXHEALTH</in-capmkt:NSESymbol><in-capmkt:NameOfTheCompany contextRef="MainI">MAX HEALTHCARE INSTITUTE LIMITED</in-capmkt:NameOfTheCompany><in-capmkt:ScripCode contextRef="MainI">543220</in-capmkt:ScripCode><in-capmkt:MSEISymbol contextRef="MainI">NOTLISTED</in-capmkt:MSEISymbol><in-capmkt:ISIN contextRef="MainI">INE027H01010</in-capmkt:ISIN><in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">Pendency of any litigation(s) or dispute(s) (Sub-para 8-Para B)</in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="I_StageOfTheLitigationIsConcludedOrDisputeIsResolved">Regularly till the litigation is concluded or dispute is resolved</in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">New</in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting contextRef="MainI">false</in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting><in-capmkt:DateOfOccurrenceOfEventOrInformation contextRef="MainI">2026-08-07</in-capmkt:DateOfOccurrenceOfEventOrInformation><in-capmkt:TimeOfOccurrenceOfEventOrInformation contextRef="MainI">12:40:00</in-capmkt:TimeOfOccurrenceOfEventOrInformation><in-capmkt:DateOfReport contextRef="MainI">2026-08-07</in-capmkt:DateOfReport><in-capmkt:StageOfDisclosureOfLitigationOrDispute contextRef="I_DevelopmentInRelationToProceedings">Development in relation to proceedings</in-capmkt:StageOfDisclosureOfLitigationOrDispute><in-capmkt:DetailsOfLitigationOrDisputeForWhichDisclosureIsBeingMade contextRef="I_DevelopmentInRelationToProceedings">This is in continuation to our earlier intimations dated May 19, 2026, July 8, 2026 and July 24,2026, wherein we had informed about the petitions, including interlocutory petition, filed before the Honble National Company Law Tribunal, Cuttack Bench (NCLT) by the legal representatives of BRS Capital Two Pte. Limited against Kalinga Hospital
Ltd. (KHL), a subsidiary of the Company, the other shareholder of KHL from whom the Company acquired the majority equity stake and the Company.

The said petitions were listed for hearing on August 4, 2026 at 10.30 am (IST). The Company received a copy of the order passed by the Honble NCLT today i.e. August 7, 2026 at 12.40 pm (IST).</in-capmkt:DetailsOfLitigationOrDisputeForWhichDisclosureIsBeingMade><in-capmkt:DateOfOriginalLitigationDisclosure contextRef="I_DevelopmentInRelationToProceedings">2026-05-19</in-capmkt:DateOfOriginalLitigationDisclosure><in-capmkt:DetailsOfDevelopmentInRelationToTheExistingProceedings contextRef="I_DevelopmentInRelationToProceedings">The matter was heard by the Honble National Company Law Tribunal, Cuttack Bench (NCLT), on August 4, 2026. The Company and the other Respondents raised objections regarding the maintainability of the interlocutory petition on the ground of an incorrect Postal Ballot Notice annexed with the application.

The Honble NCLT observed that the defect was procedural in nature and in the interest of justice consistent with the principles of natural justice, permitted the opposite party to rectify the defect by filing an additional affidavit. The matter has been listed along with the main Company Petition for further consideration on August 19, 2026.</in-capmkt:DetailsOfDevelopmentInRelationToTheExistingProceedings><in-capmkt:LitigationAgainstParty contextRef="I_DevelopmentInRelationToProceedings">Others</in-capmkt:LitigationAgainstParty><in-capmkt:DetailsOfOtherLitigationAgainstParty contextRef="I_DevelopmentInRelationToProceedings">Against Kalinga Hospital Ltd., a subsidiary of the Company, the other shareholder of KHL from whom the Company acquired the majority equity stake and the Company</in-capmkt:DetailsOfOtherLitigationAgainstParty></xbrli:xbrl>
